| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
|
Medicine details |
|
| Medicine name | pertuzumab (Perjeta®) |
| Formulation | 420 mg concentrate for solution for infusion |
| Reference number | 3580 |
| Indication | In combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 15/06/2018 |
| NICE guidance | TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |